[go: up one dir, main page]

PL3402888T3 - Środki i sposoby leczenia hbv - Google Patents

Środki i sposoby leczenia hbv

Info

Publication number
PL3402888T3
PL3402888T3 PL17701067T PL17701067T PL3402888T3 PL 3402888 T3 PL3402888 T3 PL 3402888T3 PL 17701067 T PL17701067 T PL 17701067T PL 17701067 T PL17701067 T PL 17701067T PL 3402888 T3 PL3402888 T3 PL 3402888T3
Authority
PL
Poland
Prior art keywords
hbv
measures
treatment
methods
Prior art date
Application number
PL17701067T
Other languages
English (en)
Inventor
Ulrike Protzer
Tanja Bauer
Anna KOSINSKA
Martin MUECK-HAEUSL
Original Assignee
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) filed Critical Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Publication of PL3402888T3 publication Critical patent/PL3402888T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34Antigenic peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Catalysts (AREA)
PL17701067T 2016-01-12 2017-01-12 Środki i sposoby leczenia hbv PL3402888T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU92942 2016-01-12
EP17701067.5A EP3402888B1 (en) 2016-01-12 2017-01-12 Means and methods for treating hbv
PCT/EP2017/050553 WO2017121791A1 (en) 2016-01-12 2017-01-12 Means and methods for treating hbv

Publications (1)

Publication Number Publication Date
PL3402888T3 true PL3402888T3 (pl) 2021-04-19

Family

ID=55237880

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17701067T PL3402888T3 (pl) 2016-01-12 2017-01-12 Środki i sposoby leczenia hbv

Country Status (20)

Country Link
US (1) US10912827B2 (pl)
EP (1) EP3402888B1 (pl)
JP (1) JP6743154B2 (pl)
KR (1) KR102873711B1 (pl)
CN (2) CN116732101A (pl)
AU (1) AU2017207764B2 (pl)
CA (1) CA3002508A1 (pl)
DK (1) DK3402888T3 (pl)
ES (1) ES2834698T3 (pl)
HR (1) HRP20201873T1 (pl)
HU (1) HUE052104T2 (pl)
IL (1) IL260525B (pl)
PL (1) PL3402888T3 (pl)
PT (1) PT3402888T (pl)
RS (1) RS61118B1 (pl)
RU (1) RU2740802C2 (pl)
SG (1) SG11201805229YA (pl)
SI (1) SI3402888T1 (pl)
WO (1) WO2017121791A1 (pl)
ZA (1) ZA201802644B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
WO2017210181A1 (en) 2016-05-30 2017-12-07 Geovax Inc. Compositions and methods for generating an immune response to hepatitis b virus
KR102672900B1 (ko) * 2016-09-01 2024-06-10 (주)아모레퍼시픽 2,4-디클로로-a-(3,4-디하이드로-4-옥소-2(1H)-퀴나졸리닐리덴)-β-옥소-벤젠프로판니트릴을 포함하는 멜라닌 증진용 조성물
JP7688480B2 (ja) * 2017-04-18 2025-06-04 アルナイラム ファーマシューティカルズ, インコーポレイテッド B型肝炎ウイルス(hbv)感染を有する対象を処置する方法
CA3059446A1 (en) 2017-04-18 2018-10-25 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
CN111094547B (zh) * 2017-06-14 2024-02-09 德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) 用于纯化源自人胚胎干细胞的内胚层和胰腺内胚层细胞的方法
GB201721069D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
AU2018389786A1 (en) * 2017-12-19 2020-06-18 Bavarian Nordic A/S Methods and compositions for inducing an immune response against hepatitis B virus (HBV)
EP3837366A1 (en) 2018-08-13 2021-06-23 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
US20210267890A1 (en) * 2018-09-20 2021-09-02 University Of Saskatchewan Mucoadhesive lipidic delivery system
SG11202107510SA (en) * 2019-01-11 2021-08-30 Agency Science Tech & Res Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells
JP2022524007A (ja) * 2019-03-05 2022-04-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム B型肝炎免疫化レジメンおよび組成物
WO2020210628A1 (en) * 2019-04-10 2020-10-15 Emv Enhance (Hk) Limited Compositions and methods for improving vaccination of hyporesponsive individuals
KR20220090497A (ko) 2019-08-29 2022-06-29 비르 바이오테크놀로지, 인코포레이티드 B형 간염 바이러스 백신
EP4074336A4 (en) * 2019-12-13 2024-09-04 Grand Theravac Life Science (Nanjing) Co., Ltd. PHARMACEUTICAL COMPOSITION AND ITS USE
WO2021163622A1 (en) * 2020-02-14 2021-08-19 Geovax, Inc. Vaccines and uses thereof to induce an immune response to sars-cov2
CA3188801A1 (en) * 2020-07-08 2022-01-13 Janssen Sciences Ireland Unlimited Company Rna replicon vaccines against hbv
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines
WO2023145755A1 (ja) * 2022-01-25 2023-08-03 公益財団法人川崎市産業振興財団 経皮投与用のrnaを含む組成物および当該組成物の投与方法
WO2023250522A2 (en) * 2022-06-25 2023-12-28 Administrators Of The Tulane Educational Fund Vaccine adjuvants and methods
CN115747174A (zh) * 2022-09-15 2023-03-07 武汉大学 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用
TW202436622A (zh) 2023-03-06 2024-09-16 美商英特利亞醫療公司 用於b型肝炎病毒(hbv)基因體編輯之組合物及方法
IL322666A (en) * 2023-03-17 2025-10-01 Helmholtz Zentrum M?Nchen Deutsches Forschungszentrum F?R Gesundheit Und Umwelt Gmbh A preparation containing HBV antigen for the treatment of hepatitis B
WO2025172435A1 (en) * 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235288B1 (en) * 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
WO2006125983A1 (en) * 2005-05-23 2006-11-30 Oxxon Therapeutics Ltd Compositions for inducing an immune response against hepatitis b
WO2009056535A2 (en) * 2007-10-29 2009-05-07 Genimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
BR112012002628B1 (pt) * 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
AU2012214394B2 (en) * 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
KR101281098B1 (ko) * 2011-06-30 2013-07-02 주식회사 녹십자 B형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도
JP2017515508A (ja) * 2014-05-16 2017-06-15 イエール ユニバーシティ 慢性b型肝炎ウイルス(hbv)感染症を予防または処置するためのウイルス様ベシクル(vlv)ベースのワクチン

Also Published As

Publication number Publication date
CN109154004A (zh) 2019-01-04
IL260525B (en) 2022-02-01
DK3402888T3 (da) 2020-11-30
CN109154004B (zh) 2023-06-06
CA3002508A1 (en) 2017-07-20
AU2017207764A1 (en) 2018-05-10
JP2019505205A (ja) 2019-02-28
US20190030158A1 (en) 2019-01-31
US10912827B2 (en) 2021-02-09
RU2018114308A3 (pl) 2020-02-13
HRP20201873T1 (hr) 2021-01-22
HUE052104T2 (hu) 2021-04-28
ZA201802644B (en) 2023-07-26
RU2018114308A (ru) 2020-02-13
RU2740802C2 (ru) 2021-01-21
KR102873711B1 (ko) 2025-10-21
ES2834698T3 (es) 2021-06-18
BR112018013387A2 (pt) 2019-03-06
RS61118B1 (sr) 2020-12-31
SG11201805229YA (en) 2018-07-30
EP3402888B1 (en) 2020-08-26
KR20180100228A (ko) 2018-09-07
AU2017207764B2 (en) 2023-04-27
CN116732101A (zh) 2023-09-12
PT3402888T (pt) 2020-12-04
JP6743154B2 (ja) 2020-08-19
SI3402888T1 (sl) 2021-02-26
NZ743654A (en) 2025-06-27
EP3402888A1 (en) 2018-11-21
WO2017121791A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
PL3402888T3 (pl) Środki i sposoby leczenia hbv
IL286888A (en) Use of pridopidine to treat depression or anxiety
IL257663B (en) Oral care compositions and methods of use
IL262301A (en) Liposomal preparation and methods of treatment
IL282048A (en) Oxysterols and methods of use thereof
LT3684377T (lt) Hepatito b infekcijos gydymo būdai
IL257105A (en) Modified cells and methods of therapy
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
IL246678A0 (en) Azepane derivatives and methods of treating hepatitis b infections
IL258147A (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon
DK3429596T3 (da) Cykliske dinukleotide forbindelser og brugs metoder
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
PT3142637T (pt) Formulações e métodos de tratamento de queratina
EP3960735C0 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
DK3244965T3 (da) Behandling af hovedpine med elektrisk stimulering
EP3681479A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
PT3548033T (pt) Compostos e respectivos métodos de utilização
LT3295951T (lt) Anti-pvrig antikūnai ir naudojimo būdai
HUE056287T2 (hu) Pancreatitis kezelése
PL3371206T3 (pl) Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka
IL251759B (en) Compositions and methods for treating insomnia
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme